<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87529">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140151</url>
  </required_header>
  <id_info>
    <org_study_id>ML29258</org_study_id>
    <nct_id>NCT02140151</nct_id>
  </id_info>
  <brief_title>Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Eyes With Nonexudative AMD Trial: A Multicenter, Prospectively Randomized, Masked and Controlled, Interventional Investigator Sponsored Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Desert Retina Consultants, MC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California Desert Retina Consultants, MC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether quarterly injections of Ranibizumab may prevent eyes with
      dry age-related macular degeneration from progressing to wet age-related macular
      degeneration (AMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospectively randomized, masked and controlled, interventional
      investigator sponsored phase I/II study of subjects with high-risk nonexudative age-related
      macular degeneration (AMD) treated with intravitreal ranibizumab quarterly for prophylaxis
      of conversion to exudative age-related macular degeneration.

      The objective of this study is to investigate the safety and efficacy of prophylactic
      anti-vascular endothelial growth factor (VEGF) therapy with ranibizumab to prevent the
      development of exudative AMD in eyes with high-risk nonexudative AMD.  In addition, baseline
      characteristics of high-risk eyes (fundus features, optical coherence tomography (OCT)
      parameters and genetic profile) will be evaluated to determine their predictive value in
      conversion to exudative AMD.  The effect of ranibizumab on the atrophic component of AMD
      will also be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Development of exudative AMD</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Development of choroidal neovascularization (conversion) defined by the presence of leakage on fluorescein angiography (FA) and fluid within or below the retina or below the retinal pigment epithelium seen on spectral-domain optical coherence tomography (SD-OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vision change</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in best-corrected visual acuity (BCVA) from baseline at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision loss</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of eyes losing &lt; 5, 10, and 15 letters on EDTRS chart at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of injections required in eyes that convert from dry to wet AMD during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline predictive factors</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline demographic, genetic and ocular characteristics predictive of development of wet AMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of geographic atrophy (GA)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Development of geographic atrophy (GA) as detected by fundus photography (FP) and/or fundus autofluorescence (AF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular adverse events</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence and severity of ocular adverse events, as identified by eye examination and imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse events</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence and severity of other adverse events, as identified by physical examination or subject reporting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment. Observation only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quarterly Ranibizumab 0.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quarterly intravitreal injection of 0.5mg ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <arm_group_label>Quarterly Ranibizumab 0.5mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult over 50 years old

          -  Able to sign informed consent and comply with the study protocol for the duration of
             two years

          -  Nonexudative age-related macular degeneration (AMD) in one eye (study eye)

          -  History of exudative AMD in one eye only (fellow eye) diagnosed within 5 years of
             study enrollment

        Exclusion Criteria:

          -  Participation in another simultaneous medical investigation or clinical trial

          -  Patient is pregnant, lactating, or premenopausal and not using adequate contraception

          -  Known serious allergies to ranibizumab, fluorescein dye, drugs for pupillary
             dilation, topical anesthetic, sterilizing solution (e.g. Betadine solution)

          -  Presence of ocular conditions with increased risk of choroidal neovascularization
             (CNVM) or pigment epithelial detachment (PED), including presumed ocular
             histoplasmosis syndrome (POHS), traumatic choroidal rupture, angioid streaks,
             pathologic myopia (spherical equivalent of  ≥ -8 diopters or axial length of ≥ 25
             mm), multifocal choroiditis, macular choroidal nevus, polypoidal choroidal
             vasculopathy (PCV), idiopathic central serous chorioretinopathy (ICSC), etc.

          -  History of vitrectomy in the study eye

          -  History of cataract surgery within 3 months of enrollment

          -  History of yttrium aluminum garnet (YAG) capsulotomy within 1 month of enrollment

          -  History of intraocular or periocular corticosteroid therapy within the past 90 days

          -  History of therapeutic radiation in the region of the study eye.

          -  Presence of media opacity that would preclude adequate examination and/or imaging

          -  Concurrent macular conditions that would affect the study parameters (epiretinal
             membrane, macular hole, macular edema) or require treatment within the duration of
             the study

          -  Any progressive ocular condition (uncontrolled glaucoma, diabetic retinopathy,
             uveitis) that may affect the visual acuity for the duration of the study

          -  Active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye
             at enrollment

          -  Presence of any advanced systemic condition that may hinder the patients
             participation and completion of the study

          -  Concurrent use of systemic anti-VEGF therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maziar Lalezary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California Desert Retina Consultants</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maziar Lalezary, MD</last_name>
    <phone>760-340-2394</phone>
    <email>mlalezary@desertretina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Depaz</last_name>
      <phone>650-988-7480</phone>
      <email>sdepaz@ncrva.com</email>
    </contact>
    <investigator>
      <last_name>Alok Bansal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Wieland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rahul Khurana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Palmer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Desert Retina Consultants</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Walther</last_name>
      <phone>760-340-2394</phone>
      <phone_ext>229</phone_ext>
      <email>kwalther@desertretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Maziar Lalezary, MD</last_name>
      <phone>760-340-2394</phone>
      <email>mlalezary@desertretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maziar Lalezary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clement K Chan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven G Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Coast Retina Medical Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meredith Persons</last_name>
      <phone>415-972-4607</phone>
      <email>mpersons@westcoastretina.com</email>
    </contact>
    <investigator>
      <last_name>Sara Huag, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Jumper, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur Fu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandon Lujan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bob Johnson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rich McDonald</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Williams, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristi Livermont</last_name>
      <phone>605-719-3307</phone>
      <email>klivermont@bhrei.com</email>
    </contact>
    <investigator>
      <last_name>Prema Abraham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arunan Sivalingam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>April 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amd</keyword>
  <keyword>non-exudative macular degeneration</keyword>
  <keyword>exudative macular degeneration</keyword>
  <keyword>age-related macular degeneration</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>anti-VEGF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
